Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database

Abstract

Our study showed that neo-/adjuvant chemotherapy using T irrespective of previous chemotherapy (AC or non-AC) was associated with significantly increased risk of CHF compared with AC-based chemotherapy in Korean patients with early breast cancer.

Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data

“…LV dysfunction during the use of trastuzumab has been defined as a decline in LVEF of at least 10% below normal or symptomatic heart failure according to protocols in previous clinical trials [8,22]. Regarding the interval of monitoring LV systolic function, current cardiology and oncology guidelines recommend serial examination of LVEF every 3 months during and once after completion of trastuzumab treatment in the adjuvant setting for patients with breast cancer.…”

Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review

“…In several studies that examined the effect of systemic treatments on cardiovascular problems, information on risk factors such as obesity or smoking status were not available in either the claims or the registry data. 48 This absence of prognostic data is an established issue of RWD, especially in retrospective databases where researchers do not control the data collection. 49 In these settings, failure to include all relevant confounders and to exclude all irrelevant confounders can lead to biased estimates of treatment effects.…”

Myocardial dysfunction in breast cancer survivors: ‘you can observe a lot by just watching’

“…Observations from epidemiological studies have highlighted the link between anthracycline exposure and a spectrum of cardiotoxicities from impairment in GLS to severe cardiomyopathy over a timeframe ranging from the acute setting to many years post‐treatment . The report by Jacobse et al .…”

“…[10][11][12][13] Observations from epidemiological studies have highlighted the link between anthracycline exposure and a spectrum of cardiotoxicities from impairment in GLS to severe cardiomyopathy over a timeframe ranging from the acute setting to many years post-treatment. [14][15][16][17] The report by Jacobse et al 8 studies. The strong, dose-dependent association between cumulative anthracycline dose and directionally abnormal measures of LVEF, GLS, and NT-proBNP clearly affirms the causal nature of anthracycline use and cardiac dysfunction.…”